Market Cap
US$1.9b
Last Updated
2021/04/18 23:33 UTC
Data Sources
Company Financials +
Executive Summary
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. More Details
Rewards
Risk Analysis
No risks detected for AMRN from our risk checks.
Snowflake Analysis
Excellent balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Amarin's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AMRN's weekly volatility (9%) has been stable over the past year.
Market Performance
7 Day Return
-15.3%
AMRN
3.3%
US Biotechs
1.3%
US Market
1 Year Return
-22.9%
AMRN
22.3%
US Biotechs
53.8%
US Market
Return vs Industry: AMRN underperformed the US Biotechs industry which returned 22.3% over the past year.
Return vs Market: AMRN underperformed the US Market which returned 53.9% over the past year.
Shareholder returns
| AMRN | Industry | Market | |
|---|---|---|---|
| 7 Day | -15.3% | 3.3% | 1.3% |
| 30 Day | -22.1% | -0.05% | 5.1% |
| 90 Day | -17.3% | -4.7% | 8.9% |
| 1 Year | -22.9%-22.9% | 24.2%22.3% | 56.6%53.8% |
| 3 Year | 70.7%70.7% | 32.3%25.8% | 64.4%53.6% |
| 5 Year | 167.0%167.0% | 44.2%32.7% | 120.4%95.7% |
Long-Term Price Volatility Vs. Market
How volatile is Amarin's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
An Intrinsic Calculation For Amarin Corporation plc (NASDAQ:AMRN) Suggests It's 43% Undervalued3 weeks ago | Simply Wall St
Who Has Been Buying Amarin Corporation plc (NASDAQ:AMRN) Shares?1 month ago | Simply Wall St
Amarin (NASDAQ:AMRN) Is In A Strong Position To Grow Its BusinessValuation
Is Amarin undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRN ($5.02) is trading below our estimate of fair value ($10.82)
Significantly Below Fair Value: AMRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AMRN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMRN is good value based on its PB Ratio (3.1x) compared to the US Biotechs industry average (3.7x).
Future Growth
How is Amarin forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
57.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AMRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMRN's is expected to become profitable in the next 3 years.
Revenue vs Market: AMRN's revenue (11.6% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: AMRN's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRN is forecast to be unprofitable in 3 years.
Past Performance
How has Amarin performed over the past 5 years?
25.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRN is currently unprofitable.
Growing Profit Margin: AMRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMRN is unprofitable, but has reduced losses over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare AMRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: AMRN has a negative Return on Equity (-2.87%), as it is currently unprofitable.
Financial Health
How is Amarin's financial position?
Financial Position Analysis
Short Term Liabilities: AMRN's short term assets ($879.2M) exceed its short term liabilities ($307.4M).
Long Term Liabilities: AMRN's short term assets ($879.2M) exceed its long term liabilities ($31.1M).
Debt to Equity History and Analysis
Debt Level: AMRN is debt free.
Reducing Debt: AMRN currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMRN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AMRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Amarin current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.3yrs
Average management tenure
CEO
John Thero (59 yo)
7.25yrs
Tenure
US$8,929,543
Compensation
Mr. John F. Thero has been the Chief Executive Officer of Amarin Corporation Plc since January 1, 2014 and has been its President since November 2010. Mr. Thero serves as the President of U.S. at Amarin Co...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD8.93M) is above average for companies of similar size in the US market ($USD3.79M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: AMRN's management team is seasoned and experienced (5.3 years average tenure).
Board Members
Experienced Board: AMRN's board of directors are seasoned and experienced ( 11.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Amarin Corporation plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Amarin Corporation plc
- Ticker: AMRN
- Exchange: NasdaqGM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.916b
- Shares outstanding: 393.64m
- Website: https://www.amarincorp.com
Number of Employees
Location
- Amarin Corporation plc
- Grand Canal Docklands
- Block C
- Dublin
- Co. Dublin
- 2
- Ireland
Listings
Biography
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VAS...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/18 23:33 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.